“I buy on the assumption that they could close the market the next day and not reopen it for five years.”
— Warren Buffett
A five-year buy-and-hold investment in Thermo Fisher Scientific Inc (NYSE: TMO) produced a modest positive total return over the period from August 16, 2021, through August 13, 2026. Using a dividend-reinvestment framework, a $10,000 investment grew to $10,899.78, equal to an 8.99% total return and an annualized return of 1.74%.
That outcome highlights an important point about long-term stock performance: even high-quality companies can deliver muted returns when the starting valuation is elevated, when earnings growth normalizes, or when a period of operational strength is already reflected in the share price. For TMO, the five-year holding period remained profitable, but the result was driven more by resilience than by outsized compounding.
TMO 5-Year Return Details
| Start date: | 08/16/2021 |
|
|||
| End date: | 08/13/2026 | ||||
| Start price/share: | $554.46 | ||||
| End price/share: | $595.89 | ||||
| Starting shares: | 18.04 | ||||
| Ending shares: | 18.29 | ||||
| Dividends reinvested/share: | $7.34 | ||||
| Total return: | 8.99% | ||||
| Average annual return: | 1.74% | ||||
| Starting investment: | $10,000.00 | ||||
| Ending investment: | $10,899.78 | ||||
What the 5-Year TMO Return Shows
The investment result can be summarized simply:
- $10,000 invested in TMO on 08/16/2021 became $10,899.78 by 08/13/2026.
- That equates to an 8.99% total return.
- The annualized return was 1.74%.
- Dividends modestly increased the ending share count from 18.04 to 18.29.
In other words, most of the five-year return came from a combination of limited share price appreciation and the incremental effect of dividend reinvestment. The result was positive, but well below what investors typically seek from a long-duration equity holding.
[These numbers were computed with the Dividend Channel DRIP Returns Calculator.]
Role of Dividends in TMO’s Total Return
Over the period analyzed, Thermo Fisher Scientific Inc paid a total of $7.34 per share in dividends. Reinvesting those payments added fractional shares over time, increasing the position from 18.04 shares to 18.29 shares. For a stock with a relatively low dividend yield, that contribution is helpful but not transformative; total return remains primarily tied to business performance and the market’s valuation of that performance.
This is an important distinction for TMO. Unlike higher-yielding equities where distributions can make up a substantial portion of long-term returns, Thermo Fisher has historically been more of a growth-and-quality compounder than an income vehicle. That means shareholder outcomes depend disproportionately on earnings growth, margin durability, capital allocation, and the multiple investors are willing to pay.
Current Yield and Yield on Cost
Based on the most recent annualized dividend rate of $1.88 per share, TMO has a current yield of approximately 0.32% using the ending share price of $595.89.
Another useful measure is yield on cost, which compares the current annualized dividend with the original purchase price. Using the starting price of $554.46 per share, the yield on cost is approximately 0.34%.
That figure remains low, reinforcing the broader point: TMO’s long-term investment case is generally centered on operating performance and capital appreciation rather than current income.
Why a Strong Business Can Still Produce Muted Stock Returns
A restrained five-year return does not necessarily imply business weakness. Stock returns over a defined period can be held back by several factors, including:
- Starting valuation: buying at a high earnings multiple can compress future returns even if the company continues to execute.
- Normalization after unusually strong demand: periods of exceptional revenue growth are often followed by slower comparisons.
- Low dividend support: for lower-yielding stocks, income contributes relatively little to total return.
- Multiple compression: if the market assigns a lower valuation over time, shareholders may see limited gains despite rising profits.
Those dynamics are especially relevant for large-cap life sciences and diagnostics companies, where premium valuations can persist for long stretches but still leave little margin for disappointment. In that setting, the quality of the business matters greatly, but entry price still shapes realized returns.
Bottom Line
Thermo Fisher Scientific delivered a positive five-year buy-and-hold result, but it was a subdued one. A $10,000 investment grew to $10,899.78, with dividends contributing incremental gains through reinvestment. The key takeaway is that total return over a five-year horizon depends not only on the strength of the underlying company, but also on the valuation paid at the outset and the degree to which future growth was already priced in.
Here’s one more investment quote before you go:
“If I’ve learned one thing in this life it’s this: even if you lose, don’t lose the lesson.” — Daymond John
